← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin
limaprost
B01AC28
Adult Dosing
- Lumbar spinal stenosis: 5 mcg orally 3 times daily
- Ischemic symptoms associated with thromboangiitis obliterans: 5 mcg orally 3 times daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Improvement of ischemic symptoms (ulcer, pain, and coldness) associated with thromboangiitis obliterans
- Improvement of subjective symptoms (lower extremity numbness, pain, and walking ability) associated with acquired lumbar spinal stenosis
Mechanism of Action
- Prostaglandin E1 (PGE1) analogue
- Exerts vasodilatory effects, increases peripheral blood flow, and inhibits platelet aggregation
- Improves nerve blood flow and cauda equina microcirculation in lumbar spinal stenosis
Contraindications
- Hypersensitivity to limaprost or any component of the formulation
- Pregnancy or suspected pregnancy
- Patients with bleeding tendencies or active bleeding
Adverse Reactions
- Gastrointestinal: Diarrhea, abdominal discomfort, nausea, gastric pain
- Cardiovascular: Palpitations, flushing, blood pressure decrease
- Hematological: Increased bleeding tendency
- Nervous system: Headache, dizziness
Drug Interactions
- Anticoagulants (e.g., warfarin) and antiplatelet agents (e.g., aspirin): Increased risk of bleeding due to additive antiplatelet effects
- Thrombolytic agents: May potentiate the risk of hemorrhage
Curated Content: Needs Vetting Before Put to Clinical Use